NRX PHARMACEUTICALS INC

$0.57 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About NRX PHARMACEUTICALS INC

NRX Pharmaceuticals, Inc., formerly Big Rock Partners Acquisition Corp., is a patient-focused, clinical stage pharmaceutical company. The Company is focused on developing NRX-101. NRX-101 is an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder and ZYESAMI (aviptadil), an intravenous and inhaled drug to treat respiratory failure in COVID-19. NRX-101 is designed to offer an oral, rapid-onset and sustained home-use therapy that can extend ketamine’s anti-suicidal benefit and reduce the side effects of ketamine. The Company combines D-cycloserine (DCS), a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NRX-101 is in Phase III of clinical testing.

Stock Analysis

last close $0.58
1-mo return 8.3%
3-mo return -79.5%
avg daily vol. 1.5M
52-week high 26.24
52-week low 0.49
market cap. $41M
forward pe -
annual div. -
roe -2197%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 16.4%
baraka

Subscribe now for daily local and international financial news

Subscribe